Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy
Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy
批准号:
8103864
负责人:
Robert J Binder
金额:
$16.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-02 至 2012-06-30
关键词:
Antigen-Presenting CellsAntigensAutologousBasic ScienceBloodCancer PatientCell Surface ReceptorsCellular ImmunologyClinical TrialsCommunicable DiseasesComplexCross PresentationCross-PrimingDataEquipmentFamilyFloorGoalsHeat shock proteinsImmune responseImmune systemImmunizationImmunologyInfectious AgentKnockout MiceLaboratoriesLigandsMalignant NeoplasmsMediatingModelingMolecular BiologyMolecular ChaperonesMusPeptidesPhysiologicalProceduresProcessPropertyProphylactic treatmentProteinsPublishingResearchResearch SupportRoleRunningScienceT cell responseT-LymphocyteTestingTranslationsTumor-DerivedUniversitiesVaccine DesignVaccinesWorkalpha 2-Glucoproteinsanimal facilitybasecalreticulincancer immunotherapycancer therapyclinical applicationdesignimmunogenicimmunogenicityinsightpathogenreceptorresponsesquare foottooltumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Alpha2 macroglobulin (a2M) shares its cell surface receptor CD91 with the immunogenic heat shock proteins. Based on this observation we have tested and shown that mice immunized with a2M elicit T cell responses to peptides that are chaperoned by it. Preliminary studies presented for this project have shown that the engagement of CD91 by a2M and the ability of a2M to chaperone peptides are two key properties necessary for elicitation of the immune response. No other mechanistic procedure has been provided and the aims of this project are designed to understand first the interaction of these autologous proteins with antigen presenting cells to initiate the immune response and second what the physiological relevance of these proteins are in the elicitation of immune responses. A part of this project will test the harnessing of these immune responses for vaccine design targeting cancer and infectious disease. My primary short term goals also include studying a2M in context of other CD91 ligands such as the HSPs, and their various roles in cross-presentation and cross-priming. In this regard we have developed and published numerous tools necessary for this work: purification procedures for a2M and peptide antigens, procedures for the creation of a2M-peptide complexes, tumor rejection models in both prophylaxis and therapy and currently preparing CD91 deficient knock out mice. A long term goal is the translation of the basic research of my lab into clinical applications for the treatment of cancer and an understanding of why these self proteins are immunogenic in the first place.
Our laboratory and office are located on the 10th floor of the Biomedical Science Tower of the University of Pittsburgh. The laboratory has 600 sq ft of space and is fully equipped for cellular immunology and molecular biology research and for all the projects described in this project. It is contiguous with other laboratories with the Department of Immunology and we have access to common use equipment and vast research support facilities. A pathogen-free animal facility run by the University is available in the same BST building and is AAALAC accredited.
RELEVANCE: The studies described in this project, when completed, will provide an insight to the mechanism by which alpha2-macroglobulin elicits T cell immune responses and how this response can be harnessed to generate vaccines against cancer and infectious agents. These studies will provide preliminary data leading to clinical trials in cancer patients with autologous alpha2-macroglobulin-based vaccines.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1007/s12026-011-8221-2
发表时间:
2011-08
期刊:
IMMUNOLOGIC RESEARCH
影响因子:
4.4
作者:
[Pawaria, Sudesh, Messmer, Michelle Nicole, Zhou, Yu Jerry, Binder, Robert Julian]
通讯作者:
Binder, Robert Julian
DOI:
10.1038/ncomms1524
发表时间:
2011-11-01
期刊:
Nature communications
影响因子:
16.6
作者:
[]
通讯作者:
CD91 and cancer immunosurveillance
-
批准号:10308038
-
项目类别:
-
资助金额:$34.78万
-
财政年份:2019
-
负责人:Robert J Binder
-
依托单位:
CD91 and cancer immunosurveillance
-
批准号:9897031
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2019
-
负责人:Robert J Binder
-
依托单位:
CD91 and cancer immunosurveillance
-
批准号:10524051
-
项目类别:
-
资助金额:$34.78万
-
财政年份:2019
-
负责人:Robert J Binder
-
依托单位:
Heat shock protein gp96 and Treg responses
-
批准号:9606843
-
项目类别:
-
资助金额:$19.43万
-
财政年份:2018
-
负责人:Robert J Binder
-
依托单位:
Heat shock proteins and modulation of immune responses
-
批准号:9307761
-
项目类别:
-
资助金额:$16.81万
-
财政年份:2016
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:8094481
-
项目类别:
-
资助金额:$32.85万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:8488395
-
项目类别:
-
资助金额:$30.88万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy
-
批准号:7573852
-
项目类别:
-
资助金额:$15.19万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:8290437
-
项目类别:
-
资助金额:$32.85万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:7727754
-
项目类别:
-
资助金额:$33.15万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role of CD91 and its ligands in immune response
-
批准号:7877729
-
项目类别:
-
资助金额:$33.18万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy
-
批准号:7886878
-
项目类别:
-
资助金额:$15.59万
-
财政年份:2009
-
负责人:Robert J Binder
-
依托单位:
Cancer Immunology Training Program
-
批准号:10492141
-
项目类别:
-
资助金额:$34.73万
-
财政年份:1999
-
负责人:Robert J Binder
-
依托单位:
Cancer Immunology Training Program
-
批准号:10670409
-
项目类别:
-
资助金额:$51.87万
-
财政年份:1999
-
负责人:Robert J Binder
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: